Skip to main content
NC3Rs: National Centre for the Replacement Refinement & Reduction of Animals in Research
In-person

NC3Rs/Innovate UK workshop: Delivering the Government’s alternative methods strategy – Pharmacokinetic and cardiovascular safety studies

-

Registration Details

Event date and time
-
Organiser
NC3Rs/Innovate UK

Advances in in vitro and in silico approaches are reshaping drug development by improving the prediction of efficacy, safety and pharmacokinetics. This workshop will focus on two priority targets identified in the UK Government’s 2025 alternative methods strategy: reducing reliance on animal studies in pharmacokinetic and cardiovascular safety studies.

Sessions will bring together scientists and stakeholders to discuss the current landscape and identify gaps and opportunities where replacement technologies could improve study outcomes, increase human relevance and minimise animal use. The outputs will help to define how the Government targets can be delivered in practice through supporting research collaboration and innovation.

To support this ambition we are working in partnership with Innovate UK to deliver the 'Industrial human-relevant drug models' competition, with £2M available to accelerate the adoption of non-animal approaches for pharmacokinetic prediction and cardiovascular safety.

Learn more about the Contracts for Innovation competition.

Registration

Registration closes: Friday 27 February.

This event is intended for scientists and other professional stakeholders working in related scientific fields. Please register with an institutional email address. Registrations will be reviewed in line with our terms and conditions and policy on attendance at NC3Rs events (PDF)

When registering, please indicate your preferred workshop topic for breakout sessions: cardiovascular safety, pharmacokinetics or no preference.

Agenda

TimeSession
10.00 – 10.30Registration and coffee
10.30 – 10.40Welcome address
Mike Capaldi, Newcastle University (Chair)
10.40 – 11.00The UK Government’s alternatives strategy
Anthony Holmes, NC3Rs
11.00 – 11.30Innovate UK and Business Connect overview
Grace Ford, Innovate UK 
Jessica Dobson, Innovate Business Connect 
11.30 – 12.00Industry perspective: Pharmacokinetic studies
Gareth Lewis, GSK
12.00 – 12.30Industry perspective: Cardiovascular safety studies
Carol De Santis, AstraZeneca
12.30 – 13.30Lunch
13.30 – 13.40Workshop briefing

13.40 – 15.00

(parallel sessions)

Delegates will work through a series of topics examining the gaps and opportunities for improving the uptake of alternatives to move towards Government targets.

Workshop 1 – Cardiovascular safety
How to reduce the use of non-human primates and dogs in dedicated cardiovascular safety studies by at least 50% by 2030.

Workshop 2 – Pharmacokinetics
How to reduce the use of dogs and non-human primates in dedicated pharmacokinetic (PK) studies for human medicines by at least 35% by 2030.

15.00 – 15.15Break
15.15 – 16.00Feedback from workshops 
16.00 – 16.15Discussion and Q&A 
16.15 – 17.00Networking